GT Biopharma is trading at $5.00, up 10.13%, amid a biotech-sector rally; no company-specific announcement explained the pre-market rise. - Biotech stocks were reported higher on November 6, with the biotech ETF up 2%; no report linked the rally to GT Biopharma’s move. - GT Biopharma is scheduled to present research on KRAS inhibition and NK-cell immunotherapy at SITC on November 6; the presentation was announced October 26. - Broader indexes were mixed, making the sector move more relevant than a market-wide rally.